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Abstract
Background: CD14, a receptor for lipopolysaccharides (LPS), is found in both a membrane-bound
form (mCD14) and a soluble form (sCD14). It is suggested that sCD14 is mainly released from
blood monocytes by serine protease-mediated shedding. Because α1-antitrypsin (AAT), an
inhibitor of serine proteases, has been shown to regulate CD14 expression in human monocytes
in vitro, we sought to investigate plasma levels of sCD14 and monocyte expression of mCD14 in
subjects at age 30 years with normal MM and deficient PiZZ and PiSZ genotypes of AAT.
Methods: Plasma levels of AAT and sCD14 were measured in 75 PiZZ and 34 PiSZ individuals
with normal lung function identified from the Swedish neonatal AAT deficiency screening, and in
95 age matched PiMM controls. The mCD14 expression in monocytes from 9 PiZZ, 6 PiSZ and 11
PiMM subjects was analysed by FACS and Quantitative Real Time Reverse Transcription PCA.
Results: As expected, plasma AAT concentrations were PiMM>PiSZ>PiZZ (p < 0.001). Plasma
sCD14 levels were higher in PiZZ than in PiMM subjects (p < 0.01). The expression level of mCD14
was higher (1.89-fold) in monocytes isolated from PiZZ subjects compared to PiMM controls (p =
0.00189).
Conclusion: This study is the first to show higher levels of plasma sCD14 and monocyte mCD14
expression in young, clinically healthy PiZZ AAT subjects.
Background
CD14 is a multifunctional receptor constitutively
expressed on the surface of various cells, including mono-
cytes and macrophages, but it also occurs as a soluble
form (sCD14) [1,2]. In normal serum, sCD14 is present in
relatively high concentrations (>1 µg/ml). However, in
different inflammatory and infectious diseases like sepsis
and autoimmune diseases, characterised by the activation
of monocytes and macrophages, highly elevated levels of
sCD14 can be found [3,4]. In vitro and in vivo studies show
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that endotoxin (LPS) can induce sCD14 secretion and
expression in hepatocytes [5,6]. In addition, after stimula-
tion with various agents, an increased release of sCD14 is
observed from monocytes. This suggests that sCD14 could
be used as a marker of monocyte/macrophage activation
[7,8]. The exact role of CD14 in normal and pathological
situations is not completely known. Recent findings pro-
vide evidence that sCD14 expresses systemic anti-inflam-
matory effects and functions as a modulator of cellular
and humoral immune responses [9-12].
Several studies have demonstrated a direct proteolytic
effect of serine proteases, particularly neutrophil elastase
(NE), on mCD14 resulting in the release of CD14 into the
extracellular medium [7,13]. α1-antitrypsin (AAT), a
major inhibitor of NE in the lower respiratory system, is
thought to play an essential role in limiting host tissue
injury at sites of inflammation [14]. The clinical impor-
tance of AAT is highlighted by an increased risk of devel-
oping chronic inflammatory disease, in particular chronic
obstructive pulmonary disease (COPD), in individuals
with severe AAT deficiency, PiZZ [15-18]. Severely
decreased levels of AAT in subjects with AAT deficiency
may result in increased activity of NE [19] with conse-
quent proteolysis of immune cell membrane receptors,
such as CD14, and release of soluble forms of those recep-
tors. In addition, we have recently found that AAT also
directly regulates CD14 expression and release in human
monocytes in vitro. When cells were exposed for 18 h to a
constant amount of AAT alone or in combination with
LPS, CD14 and TLR4 mRNA expression was dramatically
reduced compared to non-treated controls [20]. We
hypothesize that AAT may play an important role in mod-
ulating sCD14 levels, both as an inhibitor of NE and as a
direct regulator of CD14 expression and release, and,
therefore, subjects with AAT deficiency may have higher
CD14 expression than those with normal AAT levels.
These considerations led us to examine plasma levels of
sCD14 and blood monocyte mCD14 expression in clini-
cally healthy young adults with PiSZ and PiZZ AAT defi-
ciency relative to age and gender matched controls with
normal PiMM AAT.
Methods
Study participants
This study included 204 individuals (98 males and 106
females) aged 30 (26–34) years. AAT-deficient subjects (n
= 109; 75 PiZZ and 34 PiSZ) were recruited from the
Swedish neonatal screening study [21]. Healthy age and
gender matched controls (n = 95 PiMM) were randomly
selected from the Swedish Population Registry. Data from
physical examination and spirometry show that at the age
of 30, individuals in this cohort have normal lung func-
tion [22]. In the PiMM group, 15 were current smokers
and 16 ex-smokers; in the PiZZ groups 4 were smokers
and 9 ex-smokers, and in the PiSZ groups 4 were ex-smok-
ers. Informed consent was obtained from all individuals
and the study was approved by the ethics committee,
Lund University, Sweden and conducted according to the
Helsinki Declaration.
Sample collection
Blood was collected in tubes containing sodium heparin
or ethylenediaminetetraacetic acid (EDTA) (B-D Vac-
cutainer System, USA) and centrifuged at 2000×g at 4°C
for 10 min. Plasma was immediately separated and frozen
at -80°C and stored until assayed.
Isolation of monocytes
Blood monocytes were obtained from 26 individuals at
age 32–34 years: PiMM (n = 11, 8 males and 3 females),
PiZZ (n = 9, 5 males and 4 females) and PiSZ (n = 6, 4
males and 2 females). Monocytes were isolated using
Ficoll-Paque PLUS (Pharmacia, Sweden) as described pre-
viously [23]. The cell number was determined by using an
AC900EO Auto Counter (Swelab Instruments, AB, Swe-
den). The monocyte quantities in the preparations were
greater than 70%. Cells were centrifuged at 300 g for 5
min, re-suspended in 2 ml fetal calf serum (FCS) contain-
ing 10% Dimethyl sulfoxide (DMSO) (Merck, Germany)
and 5% D-Glucose-6-phosphate (Sigma, Germany) and
stored in a freezer at -135°C (Revco, (Kendro), Bergman
Labora, Sweden) until further analysis.
Culture of monocytes
Cells were thawed and plated in 24-well cell culture plates
(Corning Incorporated, USA) at a density of 1 × 106cells/
ml in RPMI 1640 (Gibco BRL, Life Technologies, Scot-
land) supplemented with 2 mM N-acetyl-l-alanyl-l-
glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin,
1% non-essential amino acids, 2% sodium pyruvate and
20 mM Hepes (Fluka, Chemie AG, Switzerland) without
serum at 37°C in 5% CO2. After 75 min, non-adherent
cells were removed by washing with PBS supplemented
with calcium and magnesium. Monocytes were then cul-
tured in medium for 18 h at 37°C in 5% CO2.
Fluorescence-activated cell sorting (FACS) for CD14 
expression
Monocyte CD14 expression was analysed by FACS. Cells
were thawed and washed with PBS containing 2% FCS
(Gibco BRL, Life Technologies, Scotland) and 0.01%
NaN3  (VWR International Ltd., UK). Approximately
700,000 cells were incubated with 1.5 µg/ml FITC-conju-
gated anti-human CD14 antibody (Miltenyi Biotec, Ger-
many) for 20 min in the dark at 4°C, washed and re-
suspended in 300 µl PBS containing 2% FCS and 0.01%
NaN3. FACS analysis was performed on a FACS Calibur
(Becton Dickinson, USA) and data were processed using
CellQuest Software (Becton Dickinson, USA).Respiratory Research 2008, 9:34 http://respiratory-research.com/content/9/1/34
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Monocyte lysate preparation
Human blood monocytes isolated from 26 individuals
were thawed, washed with PBS twice and then lysed in the
SideStep lysis and stabilization buffer (Stratagene, Agilent
Technologies Inc., La Jolla, CA, USA) to a final concentra-
tion of 10.000 cells/µl. The SideStep buffer inactivates cel-
lular nucleases and other enzymes, and the nucleic acids
released into the buffer are stabilized and suitable for
QRT-PCR analysis for at least 20 months when stored at -
80°C.
Quantitative Real Time Reverse Transcription PCA 
Analysis
20 µl of each SideStep cell lysate was diluted 40-fold using
SideStep buffer to a final concentration of 250 cells/µl. 1
µl of cell lysate was used in 25 µl QRT-PCR reaction with
SideStep™ II QRT-PCR Master Mix Kit, 1-Step (Stratagene,
Agilent Technologies Inc., La Jolla, CA, USA), TaqMan
primers and probes (B2M, catalog # Hs99999907_M1
and CD14, catalog # Hs00169122_g; Assay on Demand,
Applied Biosystems, Foster City, CA, USA) on the
Mx3000P Real-time PCR System (Stratagene, Agilent
Technologies Inc., La Jolla, CA, USA). Each 25 µl reaction
mix comprises 12.5 µl of 2× Brilliant II QRT-PCR master
mix, 1.25 µl of TaqMan primers and probe mix, 0.375 µl
of ROX reference dye, 0.1 µl of RT/RNase block mix, 9.77
µl of nuclease-free PCR-grade H2O and 1 µl of cell lysate.
All reactions were run in triplicate using the following
cycling parameters: 50°C/30 min, then 95°C/10 min fol-
lowed by 40 cycles of 95°C/15 sec; 60°C/60 sec. "No
Reverse Transcription (RT) control" was included for each
target using 1 µl of cell lysate in order to confirm that there
is no amplification of genomic DNA. Relative mRNA
quantification was performed using the MxPro software
application "Comparative Quantification" on the
Mx3000P normalized to β-macroglobulin gene (B2M).
Assays of sCD14
Plasma levels of sCD14 (n = 204) and culture supernatant
levels of sCD14 in monocytes (n = 26) were measured
using a commercially available sandwich enzyme-linked
immunosorbent assay (ELISA) kits (R&D Systems, UK)
according to the manufacturer's instructions. The mini-
mum detection level for sCD14 was 250 pg/ml and the
inter- and intra-assay coefficient of variation percentage
(%CV) were 6.3% and 5.5% respectively.
Plasma analysis of C-reactive protein (CRP)
The concentration of plasma CRP was analysed (n = 199)
at the Department of Clinical Chemistry in Malmoe (Mal-
moe University Hospital, Sweden) using high sensitivity
method with minimum detection level of 0.2 mg/l.
Analysis of plasma AAT
Plasma AAT was analysed by nephelometry at the Depart-
ment of Clinical Chemistry (Malmoe University Hospital,
Sweden) or by rocket-immunoelectrophoresis described
by Laurell [24]. In brief, aliquots of plasma were run for
1.5 h at 200 V on 1 mm 0.9% w/v agarose gels containing
11 mg/l anti-human AAT antibody (DakoCytomation,
Denmark). Gels were pressed between filter papers and
dried before staining with Coomassie Blue. To quantify
AAT, the distance between the tip of the rocket-shaped
immuno-precipitates and the application well, was meas-
ured. Standard curves were generated by serial dilutions of
a standard (Seronorm, Sero AS, Norway) that was run in
parallel to samples on every gel. The coefficient of varia-
tion percentage (%CV) for the inter- and intra-batch vari-
ability was 7.9% and 5.8% respectively.
Statistical analysis
The data were analysed using the Statistica software
(Series1203b, version 6.1 for Windows, Statsoft®, USA),
the SPSS software (version 12.0.1, for Windows, SPSS Inc.,
USA). All variables were analysed for the normal distribu-
tion by Kolmogorov-Smirnov test.
The one-way ANOVA combined with a multiple-compar-
isons procedure (Scheffe multiple range test) was used to
compare differences in means for both sCD14 and
mCD14 and the unpaired Student's t-test was used to
investigate differences in plasma sCD14 between genders
within the three groups (MM, ZZ and SZ). The Student's t-
test with correction for multiple comparisons was per-
formed to evaluate the differences in CD14 mRNA expres-
sion level in MM, SZ and ZZ monocytes. Plasma AAT
levels were analyzed by the Kruskal-Wallis method for
comparisons between more than two groups, and if signif-
icant, groups were compared by using the Mann-Whitney
U test and corrected for multiple comparisons (Bonfer-
roni). Tests with p < 0.05 were considered to be significant
and data are presented as mean ± SEM or SD.
Results
Plasma levels of AAT, sCD14 and CRP
As expected, the levels of plasma AAT were significantly
lower in ZZ subjects compared to both SZ and MM (p <
0.001). In agreement with previously published data [25]
the concentrations of AAT were higher in MM and ZZ
females than in males (p < 0.05 and p < 0.01, respec-
tively). Interestingly, plasma sCD14 levels were higher in
ZZ than in SZ (p < 0.05) and MM (p < 0.01) groups, but
there was no difference in sCD14 levels found between
MM and SZ groups. There was no difference in plasma
sCD14 levels between males and females within the
groups (Table 1). Increased levels of CRP indicate differ-
ent inflammatory conditions. No significant difference
was observed in mean CRP values between MM, ZZ andRespiratory Research 2008, 9:34 http://respiratory-research.com/content/9/1/34
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SZ (data not shown). Mean CRP was below the reference
value (<3 mg/l) in all three groups.
Monocyte mCD14
Since CD14 is predominantly expressed on the surface of
monocytes, we investigated the levels of mCD14 on blood
monocytes isolated from PiMM (n = 11), PiZZ (n = 9) and
PiSZ (n = 6) individuals. We first evaluated the distribu-
tion of all measured cell populations that comprise the
peripheral blood mononuclear cells (PBMCs). As shown
in Figure 1A, lymphocytes and monocytes were differenti-
ated by characteristic side and forward light-scattering
properties and confirmed by CD14 staining. However, we
found no differences among the PiMM, PiZZ and the PiSZ
individuals when comparing the fraction of CD14+ cells
with the total number of PBMC (Fig. 1A). We found no
statistical difference in the expression of monocyte
mCD14 among the groups, but the mean value of the flu-
orescence intensity (MFI) was 878.1 ± 51.2 and 742.7 ±
47.1 for PiZZ and PiSZ vs 714.5 ± 65.7 for the PiMM, sug-
gesting a higher expression of mCD14 on monocytes from
deficiency subjects (Fig. 1B).
QRT-PCR analysis of mCD14 expression in monocytes
The expression level of CD14 mRNA was also evaluated
by QRT-PCR in blood monocytes isolated from PiMM (n
= 11), PiZZ (n = 9) and PiSZ (n = 6) individuals. To deter-
mine the amplification efficiencies of both reactions, a
standard curve was generated using two-fold serial dilu-
tions of the SideStep cell lysate. The amplification efficien-
cies of 100.8% and 100.6% were obtained for CD14 and
reference B2M targets, respectively. No amplification sig-
nal was observed in "no RT control" reactions for both gene
targets that confirmed that there was no amplification of
genomic DNA. The threshold cycle differences (∆Ct)
between the gene of interest (CD14) and the normalizer
(B2M) were calculated for each sample and an average of
∆Ct for each group of individuals was used to evaluate
fold differences in CD14 expression using the delta-delta
Ct (∆∆Ct) method. The relative quantity chart of CD14
mRNA expression in normal PiMM (n = 11) and deficient
PiZZ (n = 9) monocytes showed that the CD14 expression
level was significantly higher (1.89-fold) in PiZZ mono-
cytes relative to normal PiMM (p = 0.00189). No signifi-
cant difference was found between PiSZ and PiMM
monocytes (p = 0.237) (Fig. 2).
Levels of sCD14 in monocyte culture supernatants
Soluble CD14 levels in overnight monocyte-conditioned
medium for PiZZ (n = 9), PiSZ (n = 6) and PiMM (n = 11)
subjects were measured. As illustrated in Figure 3, the
amount of sCD14 released by monocytes from PiZZ and
PiSZ subjects (mean value 10.1 ± 2.7 and 10.5 ± 3.5 pg/µg
protein, respectively) was higher than from PiMM mono-
cytes (5.0 ± 0.9 pg/µg protein), but did not reach statistical
significance (p = 0.243 and p = 0.265, respectively).
Discussion
The Z mutation of AAT leads to a conformational misfold-
ing of the protein with accumulation in the endoplas-
matic reticulum of hepatocytes and reduced export from
the liver [26]. The consequent lack of circulating AAT in
individuals with severe PiZZ AAT deficiency may lead to
development of premature pulmonary emphysema and
COPD. Pulmonary symptoms occur in the 3rd to 5th dec-
ade of life [27] and the progression of lung disease is
markedly accelerated by cigarette smoking [28]. Because
of both the lack of knowledge about the inflammatory
processes in COPD and a lack of established biomarkers,
it is not possible today to detect sub-clinical lung obstruc-
tion in time for preventive physician intervention that
could limit lung tissue damage. Therefore, many of the
COPD cases with AAT deficiency are undiagnosed or diag-
nosed too late. From 1972 to 1974, 200,000 Swedish
Table 1: Plasma concentrations of sCD14 and AAT.
Pi group sCD14 (µg/ml) AAT (mg/ml)
Total Males Females Total Males Females
MM
(n = 95)
1.26 ± 0.03 1.25 ± 0.05
(n = 38)
1.26 ± 0.03
(n = 57)
1.45 ± 0.04 1.35 ± 0.04II
(n = 38)
1.51 ± 0.06II
(n = 57)
ZZ
(n = 75)
1.40 ± 0.04*, ‡ 1.38 ± 0.05
(n = 43)
1.43 ± 0.06
(n = 32)
0.24 ± 0.01†,§ 0.22 ± 0.01**
(n = 43)
0.26 ± 0.01**
(n = 32)
SZ
(n = 34)
1.24 ± 0.04 1.24 ± 0.05
(n = 17)
1.24 ± 0.06
(n = 17)
0.61 ± 0.03† 0.57 ± 0.02
(n = 17)
0.66 ± 0.05
(n = 17)
Abbreviations used: n, number of cases; sCD14, soluble CD14; AAT, α1-antitrypsin.
Results are mean ± SEM.
* p < 0.01 vs MM,
† p < 0.001 vs MM,
‡ p < 0.05 vs SZ,
§ p < 0.001 vs SZ,
II p < 0.05 between gender within group,
** p < 0.01 between gender within group.Respiratory Research 2008, 9:34 http://respiratory-research.com/content/9/1/34
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newborns were screened for AAT deficiency. Those with
severe (PiZZ) and moderate (PiSZ) deficiency having
plasma levels of AAT that are 10–15% and 30–40% of the
normal levels have been followed prospectively [21]. The
important aims of this project were to study the natural
history and pathophysiology of AAT deficiency in child-
hood and adolescence, and to prevent lung disease. Fol-
low-up results of PiZZ and PiSZ individuals at age 30
indicate retention of normal lung function but with a
higher prevalence of respiratory symptoms compared to
age matched PiMM controls [22]. Currently there are no
reliable clinical and/or biochemical parameters that allow
us to predict who of those individuals will get COPD and
emphysema. Therefore, studies aiming to improve our
understanding of the basic mechanisms behind the devel-
opment of COPD and to translate this to the diagnosis
and/or the treatment are of great importance. We believe
that the examination of the possible difference in cellular
protein expression and the release profile between clini-
cally healthy Z and M AAT subjects may improve our
understanding of the mechanisms involved in the devel-
opment of COPD.
To our knowledge, this study is the first to demonstrate
significantly higher sCD14 levels in plasma from 30-year
old PiZZ deficiency subjects compared to age matched
PiSZ individuals and PiMM controls. It is important to
note that this finding was not related to the levels of the
The secretion of sCD14 from monocytes incubated for 18 h  at 37°C Figure 3
The secretion of sCD14 from monocytes incubated for 18 h 
at 37°C. Monocytes isolated from ZZ and SZ subjects dem-
onstrated a tendency to release higher levels of sCD14 than 
MM cells. Each bar represents mean ± SEM.
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inflammatory marker CRP nor to the smoking habits of
our study participants. Our results also indicate that ZZ
and SZ monocytes have higher surface expression of
mCD14 and that these monocytes cultured over night
release larger amounts of sCD14 than MM monocytes.
Whether higher plasma levels of sCD14 and higher
mCD14 expression in blood monocytes in the AAT defi-
cient individuals reflect specific pathophysiological
changes in these individuals and may be used as specific
marker of inflammation remains to be proven.
Several studies have demonstrated a direct proteolytic
effect of NE on mCD14 [13]. Individuals with severe AAT
deficiency arising from lower plasma levels and decreased
activity suffer a shortfall of NE inhibitor capacity. Accord-
ing to Ogushi and colleagues, Z type AAT-elastase com-
plexes are less stable than M type AAT-elastase complexes
and, compared to active M type AAT, active Z type AAT
requires twice as long to inhibit neutrophil elastase [29].
Therefore, Z AAT individuals have uncontrolled elastase
activity and increased susceptibility to emphysema as a
result of these lower levels and dysfunction of the AAT
protein. This supports the concept that lack of AAT may be
the reason for the higher sCD14 shedding in subjects with
severe AAT deficiency. Different assays usually fail to dis-
criminate between free active elastase and elastase-inhibi-
tor complexes. These limitations have hampered our
investigations of the direct relationship between plasma
levels of free NE and sCD14 in AAT deficiency subjects.
It is not yet known whether monocytes and macrophages
are the major sources of sCD14, since hepatocytes also
have been shown to produce sCD14 [5,6]. Circulating
AAT is primarily synthesized in the liver and secreted into
the bloodstream [30]. Hepatocytes from Z AAT individu-
als may express greater amounts of cell-associated CD14
protein, and therefore more of the sCD14 is released
resulting in an inverse link between plasma levels of Z
AAT and sCD14 in AAT deficiency. Further studies will be
needed to test these speculations.
The biological function of sCD14 is so far not clear. In
vitro, an excess of sCD14 is shown to inhibit LPS binding
to mCD14 and hence block cellular activation [11,31]. It
has also recently been shown that the response to low-
dose LPS instilled intratracheally is completely dependent
on CD14, whereas at higher doses the response is also
dependent on CD11b [32]. Grunwald and collaborators
have shown that binding of LPS to monocytes and LPS-
induced cell activation are abrogated by an exogenously
added high dose of sCD14 [33]. Moreover, injection of
sCD14 has been shown to decrease endotoxin-induced
mortality in a murine model [31]. It has also been dem-
onstrated that intravenous injection of an anti-CD14 anti-
body attenuates LPS-induced lung injury [34]. It also
appears that CD14 may be critical to LPS-induced airway
disease and that macrophage CD14 is sufficient to initiate
neutrophil recruitment into the airways but that CD14
may need to interact with other cell types [35].
Conclusion
CD14 is a pattern-recognition receptor that plays a central
role in innate immunity and directs the adaptive immune
responses. We for the first time demonstrate that clinically
healthy young adults with PiZZ AAT deficiency have
higher plasma sCD14 levels, show increased sCD14
release and higher mCD14 expression in peripheral blood
monocytes as compared to age matched PiMM subjects.
Our findings, therefore, argue strongly for further studies
on relationship between CD14 expression, AAT deficiency
and increased susceptibility of PiZZ subjects to develop
emphysema.
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